Näytä suppeat kuvailutiedot

SARS-CoV-2 variants Alpha, Beta, Delta and Omicron show a slower host cell interferon response compared to an early pandemic variant

Österlund Pamela; Laine Larissa; Skön Marika; Väisänen Elina; Julkunen Ilkka

dc.contributor.authorÖsterlund Pamela
dc.contributor.authorLaine Larissa
dc.contributor.authorSkön Marika
dc.contributor.authorVäisänen Elina
dc.contributor.authorJulkunen Ilkka
dc.date.accessioned2022-11-29T15:53:06Z
dc.date.available2022-11-29T15:53:06Z
dc.identifier.urihttps://www.utupub.fi/handle/10024/173390
dc.description.abstractSince the start of the pandemic at the end of 2019, arising mutations in SARS-CoV-2 have improved its transmission and ability to circumvent the immunity induced by vaccination and previous COVID-19 infection. Studies on the effects of SARS-CoV-2 genomic mutations on replication and innate immunity will give us valuable insight into the evolution of the virus which can aid in further development of vaccines and new treatment modalities. Here we systematically analyzed the kinetics of virus replication, innate immune activation, and host cell antiviral response patterns in Alpha, Beta, Delta, Kappa, Omicron and two early pandemic SARS-CoV-2 variant-infected human lung epithelial Calu-3 cells. We observed overall comparable replication patterns for these variants with modest variations. Particularly, the sublineages of Omicron BA.1, BA.2 and a recombinant sublineage, XJ, all showed attenuated replication in Calu-3 cells compared to Alpha and Delta. Furthermore, there was relatively weak activation of primary innate immune signaling pathways, however, all variants produced enough interferons to induce the activation of STAT2 and production of interferon stimulated genes (ISGs). While interferon mRNA expression and STAT2 activation correlated with cellular viral RNA levels, ISG production did not. Although clear cut effects of specific SARS-CoV-2 genomic mutations could not be concluded, the variants of concern, including Omicron, showed a lower replication efficiency and a slower interferon response compared to an early pandemic variant in the study.
dc.language.isoen
dc.publisherFRONTIERS MEDIA SA
dc.titleSARS-CoV-2 variants Alpha, Beta, Delta and Omicron show a slower host cell interferon response compared to an early pandemic variant
dc.identifier.urlhttps://www.frontiersin.org/articles/10.3389/fimmu.2022.1016108/full
dc.identifier.urnURN:NBN:fi-fe2022112968060
dc.relation.volume13
dc.contributor.organizationfi=biolääketieteen laitos, yhteiset|en=Institute of Biomedicine|
dc.contributor.organizationfi=InFLAMES lippulaiva, tutkimus|en=InFLAMES Flagship, research|
dc.contributor.organization-code2607100
dc.contributor.organization-code2607051
dc.converis.publication-id176942871
dc.converis.urlhttps://research.utu.fi/converis/portal/Publication/176942871
dc.identifier.jour-issn1664-3224
dc.okm.affiliatedauthorJulkunen, Ilkka
dc.okm.affiliatedauthorVäisänen, Elina
dc.okm.discipline3111 Biolääketieteetfi_FI
dc.okm.discipline3111 Biomedicineen_GB
dc.okm.discipline3141 Terveystiedefi_FI
dc.okm.discipline3141 Health care scienceen_GB
dc.okm.internationalcopublicationnot an international co-publication
dc.okm.internationalityInternational publication
dc.okm.typeJournal article
dc.publisher.countrySwitzerlanden_GB
dc.publisher.countrySveitsifi_FI
dc.publisher.country-codeCH
dc.relation.articlenumber1016108
dc.relation.doi10.3389/fimmu.2022.1016108
dc.relation.ispartofjournalFrontiers in Immunology
dc.year.issued2022


Aineistoon kuuluvat tiedostot

Thumbnail

Aineisto kuuluu seuraaviin kokoelmiin

Näytä suppeat kuvailutiedot